Filter by:
Topic
Resource Type
Display Only
Showing 61 Results
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Week serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies…
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
Creating a Dialogue or Just Playing for Headlines? Third Time Isn’t the Charm for ICER’s Pricing Report
Selectively picking the data to arrive at a convenient narrative — like the Institute for Clinical and Economic Review does in its third drug pricing report — should not be mistaken for good research.
Chairman’s Blog: Five Questions Decision-Makers Should Be Asking About Health Technology Agencies
NPC Board Chair and BMS SVP Michael Ryan advises caution and careful consideration of the potential risks and tradeoffs for patients by using a centralized, government-run health technology agency …
At the Heart of It: How Innovation Drives Improved Patient Outcomes
In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.
Working Together to Deliver Innovation for Patients During COVID-19 and Beyond
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
On World Hepatitis Day, Looking at Innovation That Goes Beyond a Pill
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
Walking the Walk: Taking Needed Steps to Reduce Low-Value Care
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for Addressing…
The Trade-off for Price Controls: Are We Willing to Accept Fewer Medicines?
It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
ICER Pricing Report: Creating a Dialogue or Just Playing for Headlines?
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape …
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
IVI's Jennifer Bright on Value Assessment and Transparency
In an interview, Innovation and Value Initiative Executive Director Jennifer Bright discusses how her organization has been advancing value assessment practice and the key priorities to make the…
Addressing Low-Value Care in the Time of COVID-19
The COVID-19 pandemic has had an enormous economic impact that is being felt across our communities, businesses and the overall health care system. It has placed a larger spotlight on the challenges…